Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12987355 | 0.98 | L3MBTL1 (0.44) | L3MBTL1LMNAKMT2AHPGDEPHX1 | |
| SCHEMBL12986643 | 0.94 | L3MBTL1 (0.43) | L3MBTL1LMNAKMT2AHPGDEPHX1 | |
| SCHEMBL12987123 | 0.89 | — | — | |
| SCHEMBL12987854 | 0.80 | MAPT (0.50) | L3MBTL1LMNAKMT2AHPGDALDH1A1 | |
| SCHEMBL12986428 | 0.80 | L3MBTL1 (0.33) | L3MBTL1KMT2AALDH1A1MEN1GAA | |
| SCHEMBL25311355 | 0.79 | TDP1 (0.50) | L3MBTL1LMNAKMT2AHPGDEPHX1 | |
| SCHEMBL3231082 | 0.79 | HPGD (0.47) | L3MBTL1LMNAKMT2AHPGDEPHX1 | |
| SCHEMBL314403 | 0.79 | L3MBTL1 (0.43) | L3MBTL1LMNAKMT2AHPGDEPHX1 | |
| SCHEMBL9134377 | 0.79 | TDP1 (0.50) | L3MBTL1LMNAKMT2AHPGDEPHX1 | |
| SCHEMBL6894979 | 0.79 | L3MBTL1 (0.43) | L3MBTL1LMNAKMT2AHPGDEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| US-9487500-B2 | Compounds and compositions thereof | INHIBIKASE THERAPEUTICS, INC. (US) | 2016-11-08 | — | — | US | claimed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | claimed |
| EP-2903979-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | Inhibikase Therapeutics, Inc. (US) | 2015-08-12 | — | — | EP | claimed |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | PIVOT HOLDING LLC | 2014-05-01 | — | — | US | claimed |
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | US | claimed |
| WO-2014055938-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| EP-2693876-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2014-02-12 | — | — | EP | claimed |
| WO-2012137225-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-10-11 | — | — | WO | claimed |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3882252-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12071416-B2 | Prodrugs of 4-( (1R, 3S)-6-chloro-3-phenyl-2, 3-dihydro-1H-inden-1-yl)-1,2, 2-trimethylpiperazine and 4-( (1R, 3S)-6-chloro-3-(phenyl-D5)-2, 3-dihydro-1H-inden-1-yl)-2, 2-dimethyl-1 (methyl-D3) piperazine | H. LUNDBECK A/S (DK) | 2024-08-27 | — | — | US | disclosed |
| US-20230159478-A1 | PRODRUGS OF 4- ( (1R, 3S) -6-CHLORO-3-PHENYL-2, 3-DIHYDRO-1H-INDEN-1-YL) -1,2, 2-TRIMETHYLPIPERAZINE AND 4- ( (1R, 3S)-6-CHLORO-3- (PHENYL-D5) -2, 3-DIHYDRO-1H-INDEN-1-YL) -2, 2-DIMETHYL-1 (METHYL-D3) PIPERAZINE | H. LUNDBECK A/S (DK) | 2023-05-25 | — | — | US | disclosed |
| US-20230159478-A1 | PRODRUGS OF 4- ( (1R, 3S) -6-CHLORO-3-PHENYL-2, 3-DIHYDRO-1H-INDEN-1-YL) -1,2, 2-TRIMETHYLPIPERAZINE AND 4- ( (1R, 3S)-6-CHLORO-3- (PHENYL-D5) -2, 3-DIHYDRO-1H-INDEN-1-YL) -2, 2-DIMETHYL-1 (METHYL-D3) PIPERAZINE | H. LUNDBECK A/S (DK) | 2023-05-25 | — | — | US | disclosed |
| WO-2009066917-A2 | 2-ARYLMETHYLAZETIDINE-CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVE OR ITS SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KUKJE PHARM. IND. CO., LTD. (KR) | 2009-05-28 | — | — | WO | disclosed |
| WO-2006105796-A1 | NOVEL INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2006-10-12 | — | — | WO | disclosed |
| EP-0808315-B1 | CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVES | WYETH LEDERLE JAPAN LTD (JP) | 2001-04-04 | — | — | EP | disclosed |
| US-5886172-A | ORAL PRODRUG READILY ABSORPED IN THE DIGESTIVE TRACT AND HYDROLYZED; BIOAVAILABIITY; STRONG ANTIBACTERIAL ACTIVITY ESPECIALLY AGAINST STAPHYLOCOCCUS; STREPTOCOCCUS, KLEBSIELLA AND PROTEUS | LEDERLE (JAPAN) LTD. (JP) | 1999-03-23 | — | — | US | disclosed |
| EP-0808315-A1 | CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVES | LEDERLE (JAPAN), Ltd. (JP) | 1997-11-26 | — | — | EP | disclosed |
| WO-1997021712-A1 | CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVES | LEDERLE (JAPAN), LTD. (JP) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | TPMT, BHMT2, PFAS | L3MBTL1 4514/4885LMNA 3888/4885KMT2A 645/4885 |
| US-12071416-B2 | Prodrugs of 4-( (1R, 3S)-6-chloro-3-phenyl-2, 3-dihydro-1H-inden-1-yl)-1,2, 2-trimethylpiperazine and 4-( (1R, 3S)-6-chloro-3-(phenyl-D5)-2, 3-dihydro-1H-inden-1-yl)-2, 2-dimethyl-1 (methyl-D3) piperazine | SIGMAR1, HTR3C, DRD3 | L3MBTL1 1710/4885LMNA 3205/4885KMT2A 706/4885 |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | PTK2, HCK, PTK2B | L3MBTL1 3508/4885LMNA 3839/4885KMT2A 2122/4885 |
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | POLI, MCL1, HRAS | L3MBTL1 1400/4885LMNA 2169/4885KMT2A 3522/4885 |
| US-20230159478-A1 | PRODRUGS OF 4- ( (1R, 3S) -6-CHLORO-3-PHENYL-2, 3-DIHYDRO-1H-INDEN-1-YL) -1,2, 2-TRIMETHYLPIPERAZINE AND 4- ( (1R, 3S)-6-CHLORO-3- (PHENYL-D5) -2, 3-DIHYDRO-1H-INDEN-1-YL) -2, 2-DIMETHYL-1 (METHYL-D3) PIPERAZINE | SIGMAR1, HTR3C, DRD3 | L3MBTL1 1710/4885LMNA 3205/4885KMT2A 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.